nanoComposix (now a Fortis Life Sciences company) is thrilled to announce its participation as an exhibitor at the TechConnect Nanotech 2023 conference!
Visit us at booth #306 to meet our team of experts and discover our extensive selection of standard and custom nanoparticles and learn how we can collaborate with you as your partner to bring nano-enabled technologies into real world applications
We are looking forward to meeting you there!
Attend our oral presentation, “A Diagnostic Device for Detecting Biomarkers of Organ Injury in Saliva”
The combination of nanoComposix with other Fortis portfolio companies will lead to a powerful synergy within the life science reagent space. CEO Brian Kim commented on the partnership stating, “We are excited to have nanoComposix join the Fortis Life Sciences platform, and partner with the bright and talented team in San Diego to create and commercialize high-impact nanotechnology products.”
nanoComposix CEO, Steve Oldenburg, Ph.D. founded the company with a vision of combining precisely engineered and highly characterized nanomaterials together with a multi-disciplinary team of innovative scientists to produce and bring to market nano-enabled products with unparalleled performance. Recently, nanoComposix focused its efforts on the life sciences market and has seen rapid adoption of its nanoparticles in a wider variety of diagnostic and therapeutic applications. Commenting on the partnership with Fortis, Dr. Oldenburg stated “Combining our unique nanoparticle products with accelerated development services has led to an explosion of interest in our nanoparticles and their applications. Fortis is the perfect growth partner for us to continue to provide our customers with world-class support in this dynamic market. ”
The transaction closed in June 2021.
Founded in 2004, nanoComposix, is headquartered in San Diego, CA, USA. nanoComposix was built with the mission of providing precisely engineered and highly characterized nanomaterials to a global customer base. The product portfolio contains hundreds of different variants of materials, size, shape, and surface backed by extensive technical documentation and support. Development services are provided by a technical team with extensive expertise in nanotechnology, biology, chemistry, physics, and optics. nanoComposix produced the NIST nanosilver reference material and its materials have been utilized in over 3000 peer-reviewed publications. nanoComposix is an ISO 13485 certified* company. This helps to ensure that our products and services are of the highest quality and continue to meet customer expectations.
Fortis Life Sciences is a strategic platform providing capital, expertise, and operational resources enabling the growth and success of founder-led life sciences tools companies. Fortis Life Sciences was founded in 2020, with the vision of creating a unique life sciences company focused on offering world class products coupled with the best in class customer experience.
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
]]>“Prodotti Giani’s dynamic distribution network of quality life science reagents is impressive; we are pleased to have established this partnership to leverage the nanoComposix product and service portfolio,” says Dr. Steven Oldenburg, President of nanoComposix.
This partnership will strengthen the nanoComposix brand in Italy an important channel as nanoComposix recently expands its offer with in-country distributors to improve logistics as well as product related support and expertise.
nanoComposix recently expanded their product offering to include contract services made available to support the growing demands for high-throughput automated manufacturing of point of care tests.
Prodotti, is an established brand in Italy and services the broad range of products from antibodies to flow cytometry reagents. The catalog of nanoComposix colloidal gold and gold nanoshell products make us all in one solution for the consumer.
Prodotti Gianni was founded in 1948, and is active in the distribution of ingredients for the Food, Cosmetic, and Pharmaceutical industries, as well as materials and reagents destined for Scientific Research. It is equipped with two dedicated laboratories (Food and Cosmetic), with technical staff and specialists to serve its clients.
Since its founding in 1948, Prodotti Gianni has continuously grown, becoming one of the most trustworthy suppliers in the pharmaceutical, cosmetic, agri-food, and life science markets.
In 1961 Prodotti Gianni established a Life Sciences division. Its mission has been to select and represent the most reliable and innovative providers in the field, supporting researchers in upgrading their technological tools while ensuring the quality of all products. In addition to catalog items, Prodotti Gianni offers a comprehensive custom services program.
Prodotti Gianni’s portfolio includes:
Prodotti Gianni guarantees scientific and commercial pre- and post-sale support to its customers and a reliable delivery of products in both time and quality.
Prodotti Gianni can visited online at ricerca.prodottigianni.com.
nanoComposix is a world-leading manufacturer of precisely engineered and highly characterized nanoparticles. Since 2004, they have been helping customers bring nanotechnology-enabled products to market. Their multidisciplinary technical teams provide rapid prototyping, characterization, integration, and scale-up solutions to accelerate R&D and commercialization for a wide variety of applications including biodiagnostics, topical therapeutics, nanomedicine, antimicrobial coatings, and color engineering. The company offers complete vertical integration of lateral flow assay development, including bulk production of nanoparticle reporter probes, assay development services, and high-throughput automated strip manufacturing from experts with 30+ years of experience in production of medical devices.
nanoComposix can be visited online at nanocomposix.com.
]]>With the recent expansion of the nanoComposix facility to accommodate additional BioDot reel-to-reel dispensing and lamination equipment for high throughput lateral flow test manufacturing, nanoComposix is now equipped to produce up to 10 million lateral flow tests each month under its ISO 13485:2016 certified Quality Management System*. Now, in addition to supplying gold reagent for high sensitivity in bulk and performing large-scale custom conjugations, nanoComposix offers a complete solution to efficiently bring reliable, reproducible, fully custom point-of-care tests to market.
“Having reel-to-reel manufacturing on-site expands the menu of options we can offer to our clients,” said Andre Alfaro, Director of Assay Development at nanoComposix. “We work incredibly hard to build strong and lasting relationships with our clients predicated on making sure all product development needs are met. If there is an unmet need, such as high volume manufacturing, nanoComposix will move mountains to make sure that client needs are met. No detail goes untouched throughout the process, starting with feasibility, and now persisting through to manufacturing.”
For nearly 20 years, nanoComposix has used its proprietary nanoscale toolkit to develop metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics. Under its ISO 13485:2016 certified Quality Management System, nanoComposix manufactures precisely engineered and highly characterized nanoparticles to facilitate the production of robust, reproducible nanoparticle conjugates at a commercial scale. Innovative solutions to the most challenging R&D questions are addressed through the establishment of open and collaborative relationships with clients. nanoComposix markets its products directly to consumers, and through distributors and licensing partners worldwide.
Visit nanoComposix online at www.nanocomposix.com.
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
]]>SAN DIEGO, California – nanoComposix has improved its process development for scaling up the 40 nm gold citrate particles for use in lateral flow diagnostic assays. This capability can expand production to at least 100 L at 20 OD, enough to support the manufacturing of 30–50 million lateral flow strips per month. The proprietary process developed by nanoComposix ensures that the particles remain stable and have consistent size distribution, even at larger scales, for more robust and reproducible assays. High production capacity also allows for more competitive pricing, facilitates better shipping and storage logistics, decreases cost of raw material for the customers, and shortens the lead time for bulk volume orders. nanoComposix can currently offer the scaled 40 nm citrate gold as part of its standard product offering. These nanometer gold nanoparticles are delivered with nanoComposix’s famous full characterization analysis it does for smaller scales.
nanoComposix is a world leader in nanomaterial research and development, nanoparticle processing, and quality manufacturing at small and large scales under its ISO 13485:2016 registered Quality Management System. For nearly 20 years, nanoComposix has provided nanomaterials to thousands of customers and for varied uses including Lateral Flow Assays, Drug Delivery, Plasmonics, Optical Engineering, Surface Coatings, and more.
Hundreds of different variants of material, size, shape, and surface are available as standard products and we have produced over 2000 custom core/shell, biofunctionalized, fluorescent, and magnetic nanocomposites to meet client specifications. nanoComposix produced the NIST nanosilver reference material and our particles have been utilized in more than 2000 peer-reviewed publications. All of our materials are supplied with certificates of analysis that include electron microscopy, hydrodynamic diameter, and optical data to guarantee that every batch meets product specifications.
For more information or comments please contact:
Minh Nguyen
Lateral Flow Product Manager
info@nanocomposix.com
(+1) 858 565 4227 ext. 164
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
]]>Contract and scaled manufacturing are performed on scales ranging from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials is produced in ISO13485* and cGMP compliant cleanroom facilities.
Operating since 1995, Pró-Análise as a distributor of laboratory products, such as reagents, equipment and accessories for the whole of Brazil. Throughout this period, they’ve consolidated partnerships with some of the most respected manufacturers in the segment. The high quality of the products and the speed of service due to locations in the South, Southeast and Northeast of the country, make Pró-Análise the best choice regarding the supply of laboratory products.
nanoComposix can be visited online at: nanocomposix.com
Pró-Análise can be visited online at: pro-analise.com.br
nanoComposix is a San Diego, California company that fabricates nanomaterials with unprecedented quality and control. Their multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic, and government clients for biotechnology, electronics, material science, defense, and aerospace applications. Through the establishment of open and collaborative relationships, the company rapidly generates innovative solutions to their clients’ most challenging R&D challenges. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
]]>“Increasing our manufacturing capacity is the next natural step for the company,” nanoComposix CEO & Founder, Dr. Steven Oldenburg said about the development. The company’s lateral flow team is uniquely positioned to solve sensitivity, sample matrix, and quantification challenges with ultra-sensitive nanoparticle probes, covalent binding chemistry, and new advances in quantitative smartphone-based reader technologies. “We now have complete vertical integration under our own roof,” Dr. Oldenburg said. “In addition to supplying gold reagent in bulk and performing large-scale custom conjugations, we now offer end-to-end services to help our customers bring robust, reproducible diagnostic tests to market.”
For nearly 20 years, nanoComposix has used its proprietary nanoscale toolkit to develop metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics. Under its ISO 13485:2016 certified Quality Management System*, nanoComposix manufactures precisely engineered and highly characterized nanoparticles to facilitate the production of robust, reproducible nanoparticle conjugates at a commercial scale. Innovative solutions to the most challenging R&D questions are addressed through the establishment of open and collaborative relationships with clients. nanoComposix markets its products directly to consumers, and through distributors and licensing partners worldwide.
Visit nanoComposix online at www.nanocomposix.com.
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
]]>ISO 13485:2016 is an internationally recognized standard for medical device quality management systems. One of the benefits of the system is to ensure a company’s practices continue to meet customer and regulatory requirements throughout the lifecycle of its medical device products and components. There is a considerable investment in implementing and maintaining such systems, but the payoff is twofold; customers can be confident that products are processed in a “Quality/Continuous Improvement” environment, and the QMS makes the business run better in many ways. “While we have always held ourselves to a high standard for our products and processes, we now have the formal recognition of the effort of our teams to adhere to our QMS,” said Jennifer Lindham, Quality Assurance Supervisor at nanoComposix. “We look forward to continuing to provide high quality services and products and are excited to see what new opportunities and collaborations this may bring us.”
nanoComposix is certified by Perry Johnson Registrars (PJR) of Troy, MI, which is an accredited body and registrar. “We believe that this registration is important to the industries we serve and adds value to the products we can deliver to our end customers,” said Rondii Lynberg, nanoComposix Director of Quality Assurance & Regulatory Affairs. “As a company, we thank the customers, partners, colleagues, and suppliers who have helped and supported this process.”
Standard: ISO 13485:2016
Certificate Number: C2021-01104
Scope: Design, Development and Manufacturing of Highly Characterized Nanomaterials for Medical Device Applications
Location: San Diego, CA
nanoComposix is a world-leading manufacturer of precisely engineered and highly characterized nanoparticles. Since 2004, they have been helping customers bring nanotechnology-enabled products to market. Their multidisciplinary technical teams provide rapid prototyping, characterization, integration, and scale-up solutions to accelerate R&D and commercialization for a wide variety of applications including biodiagnostics, topical therapeutics, nanomedicine, antimicrobial coatings, and color engineering. The company offers complete vertical integration of lateral flow assay development, including bulk production of nanoparticle reporter probes, assay development services, and high-throughput automated strip manufacturing from experts with 30+ years of experience in production of medical devices.
For more information or comments please contact us.
*Specific to 4878 Ronson Ct. Suite J and 4888 Ronson Ct. Suite B
]]>BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics.
nanoComposix can be visited online at: nanocomposix.com
BIOZOL Diagnostica Vertrieb GmbH can be visited online at: biozol.de/de
In this webinar, Dr. Bischof and Dr. Kholsa will be joining us from the University of Minnesota (UMN), where they work together with a nationwide team of scientists to develop methods for cell model preservation, specifically zebrafish. Their research also extends to both cryopreservation and rewarming of tissue and whole organs to lengthen the life of donated tissue and organs. Zebrafish are an important model organism for studying human genetics, cancer, other diseases, and possible pharmaceutical treatments, and there is a need for researchers to preserve and share zebrafish strains. The development of a new Research Center for Bio Preservation (ATP-Bio) at UMN is currently underway, which will house facilities for both cryopreservation and nanoparticle development.
nanoComposix plays a critical role in the development, optimization, and implementation of gold nanoparticles in this technology as part of a joint effort for a Phase II Small Business Technology Transfer (STTR) grant to improve nanowarming of zebrafish models. This collaboration takes advantage of the unique properties of gold nanoparticles and a new ultrafast warming technology being developed by Dr. Bischof to address the need to reproducibly thaw large embryos post-cryopreservation.
Please join us in welcoming Dr. Bischof and Dr. Khosla from the UMN and Dr. Aaron Saunders from nanoComposix on Wednesday, December 2nd at 11 AM PST/1 PM CST as they discuss:
John Bischof works in the area of thermal bioengineering with a focus on biopreservation, thermal therapy, and nanomedicine. His awards include the ASME Van Mow Medal and Fellowships in societies including Cryobiology, JSPS, ASME, and AIMBE. He has served as the President of the Society for Cryobiology and Chair of the Bioengineering Division of the ASME. Bischof obtained a B.S. in Bioengineering from U.C. Berkeley (UCB) in 1987, an M.S. from UCB and U.C. San Francisco in 1989, and a Ph.D. in Mechanical Engineering from UCB in 1992. After a Post-doctoral Fellowship at Harvard in the Center for Engineering in Medicine, he joined the University of Minnesota in 1993. John Bischof is now a Distinguished McKnight University Professor, Kuhrmeyer Chair in the Departments of Mechanical and Biomedical Engineering, and the Medtronic-Bakken Endowed Chair and Director of the Institute for Engineering in Medicine at the University of Minnesota. John Bischof is also Director of the NSF Engineering Research Center Advanced Technologies for Preservation of Biological Systems (ATP-Bio), which launched on September 1, 2020.
Dr. Kanav Khosla is a Post-Doctoral Associate in the Bioheat & Mass Transfer Lab at the University of Minnesota, Twin Cities. He received his MS and PhD in Mechanical Engineering at the University of Minnesota, under the mentorship of Prof John Bischof. His research focuses on the development of effective cryobanking protocols for germplasm of aquatic organisms such as fish, corals, & shrimp. A functional “Cryo-Bank” in the future will be critical to managing biodiversity, providing year-round access to embryos to grow and harvest important aquaculture species, and maintaining biomedical research models.
Aaron is a chemical engineer with more than 15 years of experience in the design, fabrication and integration of colloidal nanoparticles into applications ranging from diagnostics to photovoltaics. During his graduate work at the University of Texas at Austin and postdoctoral research at the Hebrew University in Jerusalem, he developed new methods for synthesizing multi-component particles with novel optical and catalytic properties. As a professor at the University of Colorado at Boulder his research group studied the synthesis and shape control of colloidal metal and semiconductor nanocrystals, focusing on energy harvesting and sensing applications. He moved to nanoComposix in 2011 and leads projects working with government and commercial clients to develop materials with tailored optical properties for diagnostic, sensing, security, and energy applications.
]]>CALGARY, Alberta, Nov. 12, 2020 (GLOBE NEWSWIRE) – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or “the Company”) is pleased to announce that has begun optimization of its SARS-CoV2 rapid detection test method with nanoComposix, a highly regarded life science nanotechnology company that specializes in the development and manufacturing of lateral flow rapid tests.
The purpose of optimization is to advance FluroTest’s test method from proof of concept to commercial scale production readiness as it prepares for the U.S. Food and Drug Administration’s review process.
Founded in 2004, nanoComposix has a multi-disciplinary team of scientists with backgrounds in chemistry, physics, and engineering. nanoComposix has worked with over 100 different clients to develop materials, composites and formulations with tailored optical and physical properties for a wide range of applications including medical devices, nanoparticle drug delivery, optical sensors, and consumer products.
“nanoComposix is a key development partner and has supported us extensively through the process of achieving our successful proof of concept,” noted Dr. Mauricio Arias, R&D Director and Senior Scientist. “We are entering the optimization stage of our test method development having achieved a consistent Limit of Detection (“LOD”) of 1,000 viral particles per milliliter of saliva. Based upon publicly available information for other antigen tests, our test method produces LOD results significantly below any antigen test approved by the United States Federal Drug Administration. We are highly confident in nanoComposix’s proven optimization capabilities as we move to the commercialization stage of our pandemic defense platform.”
Limit of detection is the minimum amount of target microorganisms that can be reliably detected under optimal conditions and is an essential step in determining the sensitivity of any assay and reducing the false negative results.
“We are excited to be working with FluroTest as a partner in the development of their novel SARS-CoV2 test. Our partnership leverages our core competencies in the development of nanomaterials and lateral flow assay systems to create a unique platform to achieve extremely low limits of detection comparable to that of molecular based testing methods that have become the standard for COVID-19 detection. We are confident of the outcomes we can achieve,” stated Steve Oldenburg, CEO of nanoComposix.
By combining and leveraging the disciplines of robotics automation, biochemistry (antibody labeling and binding), fluorescence detection and cloud computing, FluroTest believes it is creating the first pandemic defense platform (the “Platform”) of its kind, achieving throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes.
FluroTest believes its Platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to: colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.
Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the early stages of research and development and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus. The Platform is currently pending FDA approval. In addition, FluroTest requires additional capital in the near-term to further the development and deployment of its testing device and will be seeking equity investors and is exploring strategic partnerships in connection with the same.
About FluroTech (TSXV: TEST) (OTCQB: FLURF)
FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples for specific applications. Using technology that was first developed at the University of Calgary, FluroTech has created a two-part solution comprised of its CompleTest™ platform technology and consumable testing kits. Its accuracy has been independently validated. FluroTech continues to develop additional applications for the CompleTestTM platform technology. To learn more, visit FluroTech.com
About FluroTest LLC
Unlike firms developing individual tests for the detection of SARS-CoV2, FluroTest is developing a complete system for surge-scale testing of viruses and other pathogens to be deployed in environments where significant numbers of people need to be tested rapidly and frequently. By combining and leveraging the disciplines of robotics automation, biochemistry (antibody labeling and binding), fluorescence detection and cloud computing, FluroTest believes it is creating the first pandemic defense platform of its kind.
FluroTest is seeking additional capital in the near-term and will also be exploring strategic partnerships with manufacturing and distribution companies to advance the deployment of the patent pending platform it is developing. To learn more, visit FluroTest.com
About nanoComposix
nanoComposix (www.nanocomposix.com) has been providing customers with precisely engineered and highly characterized nanoparticles for more than 15 years, offering hundreds of different variants of material, size, shape, and surface functionalization as stock products. Their multidisciplinary technical teams provide rapid prototyping, characterization, integration, and scale-up solutions to accelerate R&D and commercialization for a wide variety of applications. nanoComposix is committed to helping its customers bring nanotechnology-enabled products to market and executes contract manufacturing on scales ranging from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials are fabricated in ISO13485 and cGMP compliant cleanroom facilities.
]]>Toronto, Ontario – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. (“Orpheus”) are pleased to announce the successful completion of the initial feasibility studies with its polypeptide detection candidates for CoviSafe™.
Therma & Orpheus are also pleased to announce the engagement of nanoComposix Inc. (“nanoComposix”) to complete the development of CoviSafe™. NanoComposix is uniquely positioned to begin final development of CoviSafe™ and to assist Therma & Orpheus with defining optimal reagents and chemistries necessary to make CoviSafe™ an ultrasensitive, rapid, saliva-based, point of care lateral flow test for SARS-CoV-2 and enable final development of CoviSafe™.
NanoComposix is a global supplier of precisely engineered, highly characterized nanoparticles and provides full-service lateral flow assay development solutions for its customers. NanoComposix has more than a decade of experience incorporating novel nanoparticles and chemistry into diagnostic assays and will leverage its extensive experience in ultrasensitive, rapid, quantitative, point of care rapid tests to bring CoviSafe™ to market.
Therma & Orpheus will retain the commercial rights to the resulting CoviSafe™ rapid saliva test. The companies will work in parallel to complete development of the test prior to clinical testing for submission to Health Canada, FDA and to attain European CE marking to introduce CoviSafe™ into markets as quickly as possible.
Dr. Steven Oldenburg, Founder & CEO of nanoComposix, commented, “nanoComposix is pleased to work alongside the dynamic teams at Therma Bright and Orpheus to accelerate both the product development cycle and commercial launch of the CoviSafe™ assay.”
Rob Fia, CEO Therma Bright, commented, “We are pleased to complete the feasibility study and advance to next steps in the development of CoviSafe™. It is exciting to work with such a proactive and experienced team at nanoComposix. NanoComposix will assist Therma & Orpheus to fast track the development of CoviSafe™.”
Saied Babaei, CEO of Orpheus, commented, “With the help of nanoComposix, we will be able to accelerate our work and bring this critical test to the market quicker. We are impressed by nanoComposix’s expertise in working with Orpheus’ biological candidates to enhance sensitivity and specificity of the CoviSafe™ rapid test. We feel the addition of this strong technical team will further de-risk and accelerate the regulatory process and clinical validation of our saliva-based rapid test.”
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated to relieve the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.Therma Bright and Orpheus are not making any express or implied claims that its product, CoviSafe™, has the ability to eliminate or cure COVID-19 (or SARS-CoV-2 virus).
Therma Bright Inc. trades on the TSXV (TSXV: THRM) (FSE: JNX). For more information, visit: www.thermabright.com and www.coldsores.com
Orpheus Medica is a fully integrated research-driven Canadian biotech company focused on the development and commercialization of innovative diagnostic and therapeutics for unmet medical needs. Orpheus, with its fully integrated R&D infrastructure, provides strategic partners and collaborators access to its proven and proprietary discovery and development of novel biopharmaceutical products. Our team has over 15 years of proven and validated computational capabilities for analysis and optimization of single-domain antibodies and other polypeptides.
NanoComposix is a San Diego, California company with the world's largest variety of metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics. GMP and ISO13485 compliant manufacturing methods produce precisely engineered and highly characterized nanoparticles that provide high levels of consistency and performance. Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. NanoComposix markets their products directly and through distributors and licensing partners worldwide.
]]>nanoComposix (www.nanocomposix.com) has been providing customers with precisely engineered and highly characterized nanoparticles for more than 15 years, offering hundreds of different variants of material, size, shape, and surface functionalization as stock products. In addition, the company produces custom nanomaterials including core/shell, biofunctionalized, fluorescent, and magnetic nanocomposites to meet individual client specifications. Each material is provided with a certificate of analysis that includes a full suite of characterization services including optical data, electron microscopy analysis, hydrodynamic diameter, and pH readings to verify that every sample satisfies the company’s product specifications. nanoComposix is committed to helping its customers bring nanotechnology-enabled products to market and executes contract manufacturing on scales ranging from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials are fabricated in ISO13485 and cGMP compliant cleanroom facilities.
Amplicon Biotech is a distributor that provides Life Sciences reagents & supplies, instrumentation, and technical support to research, pharmaceutical, and diagnostic centers across India. The company offers products and services for applications ranging from immunoassay and diagnostic development to cell cultures, molecular biology, and testing kits for food safety. Amplicon Biotech also offers custom services including peptide and protein synthesis, antibody customization, next generation DNA sequencing, and more. Centrally located in New Delhi, Amplicon Biotech’s technical team is experienced and equipped for providing outstanding service and support to its customers throughout the surrounding area.
Many of Amplicon Biotech’s clients are developing lateral flow diagnostic technologies that will benefit from sensitivity enhancements offered by conjugating to high quality nanoparticles from nanoComposix. The two companies are enthusiastic to work together to see what new opportunities result from this collaboration.
nanoComposix can be visited online at: www.nanocomposix.com
Amplicon Biotech can be visited online at: www.amplicon.in/
nanoComposix is a San Diego, California company that fabricates nanomaterials with unprecedented quality and control. Their multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic, and government clients for biotechnology, electronics, material science, defense and aerospace applications. Through the establishment of open and collaborative relationships, the company rapidly generates innovative solutions to their clients’ most challenging R&D challenges. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
]]>Our facility will remain open, with the following modifications to our company policies, in accordance with the advice of the CDC and WHO as well as state and federal government:
If you have ordered a reagent from us in the last week and have been recently notified of a closure to your facility, please notify us of any closure so we can either arrange to postpone the shipment or cancel the order.
As the current status is rapidly in flux, we will make every effort to notify our customers if the current situation prevents us from continuing or modifying our current operation plan.
Thank you for your continued support,
Dr. Steve Oldenburg
CEO, nanoComposix
EM Japan supplies its customers with reagents and equipment to support imaging, calibration, and microscopy-related research and material analysis. The company focuses on provision of products that are useful for electron microscope users around the country. EM Japan provides devices and expendable supplies to support sample preparation of electron microscope samples. nanoComposix manufactures nanoparticles that are precisely engineered and highly characterized. Their highly uniform products and batch to batch consistency are key factors that fit well into EM Japan’s portfolio of product offerings, which aims to provide products to electron microscope users throughout Japan.
nanoComposix can be visited online at: www.nanocomposix.com
EM Japan can be visited online at: https://www.em-japan.com/
nanoComposix is a San Diego, California company that fabricates nanomaterials with unprecedented quality and control. Their multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic, and government clients for biotechnology, electronics, material science, defense and aerospace applications. Through the establishment of open and collaborative relationships, the company rapidly generates innovative solutions to their clients’ most challenging R&D challenges. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
]]>Vaccines are currently being developed for CMV, but improved diagnostics are essential to qualify candidates for enrollment in large scale clinical trials. One major problem with current diagnostics is their inability to detect the low antibody titers present in some infected individuals, leading to false negative readings prior to enrollment in vaccination trials. CMV has a low rate of seroconversion, such that only 0.5% of individuals infected with the virus will develop an immune response within a given year. As a result, the change in infection rate between a vaccine-protected population and an unprotected population may be very small. Thus, the diagnostics need to be very sensitive to ensure that clinicians can observe and accurately quantify those changes. Specifically, people who falsely appear not to have been infected with the virus and test positive at the end of the trial will obscure the efficacy of the vaccine. Clinical trials are conducted on large scales involving tens of thousands of individuals, so even small numbers of false readings will have a significant impact. Exquisitely sensitive testing methods are crucial.
This project focuses on the development of a lateral flow assay (LFA) to rapidly and accurately screen individuals for the presence or absence of IgG and IgM antibodies against CMV by placing a blood sample on a test trip outfitted with a simple visual signal readout, similar to the concept of a home pregnancy test. Integrating plasmonic gold nanoshells as the detector element provides ultra-high contrast to increase test sensitivity to overcome this obstacle. “Gold nanoshells demonstrate at least an order of magnitude greater sensitivity than standard lateral flow diagnostics,” said Dr. Richard Baldwin, VP of Research at nanoComposix. “This improvement will dramatically reduce the number of false readings that cloud the results of clinical trials all too often.”
Dr. Diamond, Chair and Professor in the Department of Experimental Therapeutics at the City of Hope – Beckman Research Institute, brings invaluable expertise to the team as a specialist in infectious pathogens, including herpesvirus strains such as HIV and CMV. According to the CDC, more than half of adults over age 40 have been infected with CMV and though there is no cure, healthy individuals often show no symptoms of infection. A major problem arises, however, when seropositive pregnant mothers unknowingly transmit the virus to their babies. Congenital CMV afflicts 0.64% of babies born in the United States today. Among those infected, approximately 20% will develop serious complications including hearing and vision loss, intellectual impairment, small head size, and other neurological disorders. For others with compromised immune systems, CMV can even be fatal. “Preventing pregnant women from contracting CMV will have an immediate and significant impact to reduce the number of newborn babies infected with CMV across the globe,” said Dr. Baldwin. “A rapid diagnostic and an effective vaccine for prevention are essential.”
nanoComposix is a world leading manufacturer of precisely engineered and highly characterized nanoparticles. Since 2004, they have been helping customers bring nanotechnology-enabled products to market. Their multidisciplinary technical teams provide rapid prototyping, characterization, integration, and scale-up solutions to accelerate R&D and commercialization for a wide variety of applications including biodiagnostics, topic therapeutics, nanomedicine, antimicrobial coatings, and color engineering.
]]>Since the epidemic began nearly 40 years ago, AIDS-related illnesses have claimed more than 35 million lives around the world. Most of the vaccine development since that time has focused on designing antigens, rather than developing methods for controlled antigen delivery. The rapid mutation of the virus and integration into the host genome make HIV particularly challenging to protect against, and the most effective vaccine to date demonstrated only 31% efficacy.
The team at nanoComposix will focus on achieving controlled delivery to antigen presenting cells (APCs) by using mesoporous silica nanoparticles (MSNPs) as a delivery vehicle for its HIV vaccine. MSNPs are non-toxic and can be engineered with a range of sizes, porosities and surface functionalizations. The dimensions of their pores and overall particle dimensions can be tuned by controlling the synthetic conditions during fabrication. Scientists at nanoComposix have exquisite control over these parameters, enabling the company to offer more than 50 different silica-based nanomaterials in its product catalogue, including a variety of mesoporous options.
“We’ve assembled an exceptional group of scientists to take on this challenge through a unique approach,” said Dr. Philippe Saint-Cricq-Riviere, Senior Scientist at nanoComposix. Dr. Diamond, Chair and Professor in the Department of Experimental Therapeutics at City of Hope, has devoted many years to HIV-related research and therapy development. “This work combines the expertise of immunology experts and nanoparticle synthesis specialists to develop a new class of immunogen delivery vehicles,” Saint-Cricq-Riviere said. “An interdisciplinary team of skilled scientists and innovative thinkers is our best weapon for fighting HIV.”
MSNPs have spacious internal pores that allow them to load large quantities of immunogens inside for transport and controlled delivery. Modifying the internal pore surface chemistry enables selective loading of immunogenic messenger RNA and toll-like receptor (TLR) proteins into MSNP pores based on chemical recognition and compatibility. The external particle surfaces are easily functionalized to facilitate targeted delivery to APCs. Additionally, a polymer coating will serve as a gatekeeper to the nanoparticle pores, ensuring that molecular cargo is released only in the correct cellular compartment. In biological fluids, silica nanoparticles can be engineered to dissolve slowly, releasing internal cargo through controlled release over time. This innovative material benefits from precise spatial and temporal control, engineered to give the particles ample opportunity to reach their APC targets before gradual drug release begins. This strategy is designed to avoid many of the pitfalls faced by previous approaches to HIV vaccine development.
nanoComposix is a cGMP manufacturer with more than 15 years of experience fabricating precisely engineered and highly characterized nanoparticles. They strive to assist their customers through the process of bringing nanotechnology-enabled products to market. Their multidisciplinary technical teams provide rapid prototyping, characterization, integration, and scale-up solutions to accelerate R&D and commercialization for a wide variety of applications including biodiagnostics, topical therapeutics, nanomedicine, antimicrobial coatings, and color engineering.
]]>Since 2004, nanoComposix has provided development, fabrication, processing and scale-up to accelerate the commercialization of nanomaterial in several applications that include in-vitro diagnostics, therapeutics, devices, plasmonic, and preclinical drugs. NanoComposix is focused on the development and scale up of cGMP manufacture of colloidal nanomaterials for its customers.
For more information about nanoComposix, please visit nanocomposix.com.
For more information or comments please contact:
Tom Darlington
VP of Operations
858-565-4227, ext. 125
tom.darlington@nanocomposix.com
NanoComposix specializes in the fabrication and characterization of nanoparticles, offering hundreds of standard products in its catalog, all of which can be manufactured under GMP quality guidelines. nanoComposix also produces nanomaterials on a custom basis, including a range of core/shell, biofunctionalized, fluorescent, and magnetic nanocomposites to meet client specifications. Each sample is provided with a certificate of analysis listing a full suite of material characterization data including optical measurements, electron microscopy analysis, hydrodynamic diameter, and pH readings to ensure compliance with the company’s stringent product specifications. nanoComposix is a scalable contract manufacturer with the ability to produce materials on scales ranging from milligrams to kilograms. Nanomaterials for medical devices and clinical trials are fabricated in ISO13485 and cGMP compliant cleanroom facilities. By leveraging its unique library of nanomaterials and production capabilities, nanoComposix aims to help customers rapidly bring nanotechnology-enabled products from conception to commercialization.
Veritas, founded as a venture technical trade company in 1972, is known today for its cutting-edge bioscience technologies from a range of suppliers around the world. Product areas of focus include immunology, hematology, cell biology, microbiology, and expression monitoring, in addition to HLA analysis, drug screening and toxicity testing, environmental and food testing, and regenerative medicine. The company uses its strategic position to focus on providing excellent sales, marketing, and technical support for a suite of products that are directly aligned with its goals and target markets. Veritas takes a unique approach to customize products and consultations to give each sector the attention it deserves and strategically optimize customer experience. Their central office and main distribution center are in the Hamamatsucho Minato-ku district of Tokyo, with sales and marketing personnel who make frequent visits to customers throughout Japan. This model allows them to maintain their commitment to building long-term relationships by gaining the trust and mutual respect of their client base.
Veritas will leverage nanoComposix’s range of products to target diverse techniques and life science assays. Both companies are eager for the opportunity to work together to provide excellent products and customer service to customers across Japan.
nanoComposix can be visited online at: www.nanocomposix.com
Veritas can be visited online at: www.veritastk.co.jp
nanoComposix is a San Diego, California company that fabricates nanomaterials with an unprecedented level of quality and control. Their multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic, and government clients for biotechnology, electronics, material science, defense and aerospace applications. Through the establishment of open and collaborative relationships, the company rapidly generates innovative solutions to their clients’ most challenging R&D challenges. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
]]>nanoComposix (www.nanocomposix.com) has been providing customers with precisely engineered and highly characterized nanoparticles for the last 15 years, offering hundreds of different variants of material, size, shape, and surface functionalization as stock products. In addition, the company produces custom nanomaterials, from core/shell particles to biofunctionalized, fluorescent, and magnetic nanocomposites to meet individual client specifications. Each material is provided with a certificate of analysis that includes a full suite of characterization services including optical data, electron microscopy analysis, hydrodynamic diameter, and pH readings to verify that every sample satisfies the company’s product specifications. nanoComposix executes contract manufacturing on scales ranging from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials are fabricated in ISO13485 and cGMP compliant cleanroom facilities.
CliniSciences is a European distributor of Life Science reagents and instruments for immunology, cell biology, and molecular biology. Other research areas they support include stem cells, cell & plant biology, apoptosis, neuroscience, metabolism, and protein studies. The company is based in France and has distribution subsidiaries in many countries across Europe, each with local representatives in the field to provide customers with resources and services to support them through the various stages of diagnostic development and fundamental research. In addition to distributing products from a wide range of vendors around the world, CliniSciences offers consultation and a suite of custom services, ranging from custom gene targeting in cell lines to in vivo infectious disease modeling and ultrasensitive biomarker testing.
The nanoComposix product offerings fit in well with the range of products and services supported at CliniSciences. The two companies are enthusiastic to see what new opportunities result from this partnership.
nanoComposix can be visited online at: www.nanocomposix.com
CliniSciences can be visited online at: www.clinisciences.com
]]>“The fundamental limits of sensitivity in lateral flow diagnostics are dictated by the reporter nanoparticle” said Dr. Steven Oldenburg, Founder and CEO of nanoComposix. “With more than a decade of experience building precisely engineered and highly characterized nanomaterials for thousands of customers worldwide, nanoComposix is uniquely positioned to provide the improved particles and chemistry necessary for ultrasensitive, rapid, quantitative, point of care lateral flow diagnostic tests.”
NanoComposix’s proprietary gold nanoshells provide up to a 20-fold increase in sensitivity compared to 40 nm diameter gold nanospheres enabling lateral flow assay tests that were previously not possible. Unique “bare” gold nanoparticles with a highly displaceable surface optimized for passive adsorption generate stable and reproducible conjugates. Covalent conjugation chemistry improves conjugate stability in a variety of matrices, provides greater control over per particle antibody loading improving conjugate reproducibility, and, due to higher antibody binding efficiency, can reduce the antibody reagent cost of the assay. NanoComposix’s full service assay development services leverages the company’s unique expertise to provide rapid development of ISO13485 compliant assays. Services include feasibility, assay design, antibody pair selection, full strip optimization, prototype cassette design, verification and validation, and transfer to full scale production. For assay quantification, nanoComposix provides multiple reader options with an emphasis on cell phone-based reader technology.
NanoComposix is a San Diego, California company with the world’s largest variety of metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics. GMP and ISO13485 compliant manufacturing methods produce precisely engineered and highly characterized nanoparticles that provide high levels of consistency and performance. Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. NanoComposix markets their products directly and through distributors and licensing partners worldwide.
Contact:
Elizabeth Ward
nanoComposix, Inc.
4878 Ronson Ct, Ste K
San Diego, CA 92111
Tel: +1 (858) 565-4227
Fax: +1 (619) 330-2556
Email: elizabeth.ward@nanocomposix.com
Website: nanocomposix.com
The title of the STTR contract from the National Institutes of Health (NIH) is "Gold Nanoparticle Laser Warming of Cryopreserved Zebrafish Embryos". In the past decade, laboratories around the world have produced tens of thousands of different variants of zebrafish for a wide range of genetic and biomedical research. Maintaining all of these valuable variants is expensive, risky, and beyond the capacity of even the largest stock centers. Cryopreservation of zebrafish sperm, eggs and embryos is vital to the strategy of the NIH Division of Comparative Medicine, which envisions increased multi-institutional research using animal models. To date, zebrafish sperm and eggs have been successfully cryopreserved, but zebrafish embryos have not. Methods and instruments that enabled the long-term storage and transport of cryopreserved embryos would address a critical need for zebrafish researchers.
This project will develop and optimize a gold nanoparticle (GNP) based rapid-warming technology that has successfully generated viable zebrafish grown from cryopreserved embryos. Due to the large size of the embryo, traditional warming mechanisms are too slow and result in the formation of ice crystals that damage the embryos and prevent them from being viable. The key innovation of this research addresses this limitation in the warming step. Injected gold nanoparticles act as a distributed network of ultra-efficient heaters that generate warming rates of millions of °C/min when illuminated with an infrared laser. To achieve this ultrafast and reproducible warming, stable, low-toxicity GNPs with strong absorption at the laser wavelength will be fabricated by nanoComposix and a micro-injection technique developed at the University of Minnesota will be optimized to safely introduce the gold nanoparticles into the embryos. The embryos will be rapidly cooled to prevent damaging ice formation, and laser warming techniques will be optimized to increase embryo survival after thawing. The combined foundational research of Dr. Bischof and his collaborators along with the expertise in gold nanoparticle synthesis and manufacturing at nanoComposix will allow for rapid optimization and commercialization of this technology.
Gold nanoparticles from nanoComposix have extraordinary properties at the nanoscale that are enabling a wave of innovative commercial products. Many of these new applications are in the field of bio-nanotechnology, diagnostics and therapeutics. The products can be manufactured at nanoComposix under cGMP guidelines which are required for many life-science diagnostic and therapeutic product uses.
We are a San Diego, California company that fabricates nanomaterials with an unprecedented level of quality and control. Our multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic and government clients for biotechnology, electronics, material science, defense and aerospace applications. Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
This research is supported by the Office of the Director of the National Institutes of Health under Award Number R41OD024430. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Contact:
Elizabeth Ward
nanoComposix, Inc.
4878 Ronson Ct, Ste K
San Diego, CA 92111
Tel: +1 (858) 565-4227
Fax: +1 (619) 330-2556
Email: elizabeth.ward@nanocomposix.com
Website: nanocomposix.com
In this nanoComposix tutorial, our Characterization Services manager, David, gives a roundup of the importance of various nanoparticle characterization techniques and how they work.
If you need your nanoparticle characterized, we offer our services here.
We also have handbooks for nanoparticle characterization here.
]]>In this webinar, you’ll learn techniques to optimize the 7 components that are critical when developing your assay. Our lateral flow experts Rhea and Jean will teach you the secrets of often-overlooked methods to help you maximize the potential of your lateral flow assay.
]]>The second part in a series on how to accurately measure the optical spectra of solutions of nanoparticles using a UV-VIS (UV-Visible) spectroscopy. In this demo, we use an Agilent 8453 spectrophotometer to accurately measure a high concentration solution of nanoComposix's BioPure Silver Nanospheres using an analytical balance.
Video discusses:
More information about UV-Vis measurements and Plasmonic materials can be found through the following links:
Let us measure your sample for you! Find out more about our UV-Vis measurement services and other nanoparticle characterization services.
Thanks for watching! Please contact us with feedback and suggestions of what else you'd like to see from us!
]]>i-DNA Biotechnology Pte. Ltd. i-DNA is a product and service-oriented company with their headquarters and R&D laboratory facility located in Singapore. The primary focus of i-DNA is to develop, manufacture, market and distribute innovative products and services for applications in the areas of the life sciences, biotechnology, assay development and laboratory testing. In addition to providing products and assay development to its customers, i-DNA distributes research products from many leading international brands, with the aim of bringing diverse high quality research tools and solutions to its customers including offering specialized and contract research services catered to the customer’s specific requirements. With its headquarters in Singapore and a strong business network in the South-East Asia, i-DNA offers excellent customer service for its products and services in Singapore and Southeast Asia markets.
The nanoComposix products fit well with i-DNA’s product lines which are used for diverse techniques and life science assays. Both companies look forward to working together to provide excellent customer service to customers in Singapore and Southeast Asia in the coming years.
The press release can be found on the nanocomposix website link here: nanocomposix.com/blogs/news/nanocomposix-signs-agreement-with-i-dna-biotechnology-pte-ltd-for-distribution-of-its-products-in-singapore-and-malaysia
The nanoComposix website is: nanocomposix.com
The Stratech Scientific website is: i-dna.sg
We are a San Diego, California company that fabricates nanomaterials with an unprecedented level of quality and control. Our multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic and government clients for biotechnology, electronics, material science, defense and aerospace applications. Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
Contact:
Elizabeth Ward
nanoComposix, Inc.
4878 Ronson Court, Suite K
San Diego, CA 92111
Tel: +1 (858) 565-4227
Fax: +1 (619) 330-2556
Email: elizabeth.ward@nanocomposix.com
Website: nanocomposix.com
Contact:
Woe Huey Liang
i-DNA Biotechnology Pte. Ltd.
237 Pandan Loop
#07-08 Westech Building
Singapore 128424
Tel: +65 6779 0665
Email: hueyliang@i-dna.sg
Website: i-dna.sg
nanoComposix announced it that has selected and signed an agreement with Stratech Scientific Ltd. for distribution of nanoComposix nanotechnology products and services in the United Kingdom. nanoComposix is a 12 year old company that provides monodisperse and unagglomerated metal and metal-oxide nanomaterials to thousands of customers worldwide. The company has hundreds of different variants of material, size, shape, and surface are available as stock products and has produced over 2000 custom core/shell, biofunctionalized, fluorescent, and magnetic nanocomposites to meet client specifications. NanoComposix produced the NIST nanosilver reference material and its particles have been utilized in over 400 peer-reviewed publications. All materials are supplied with certificates of analysis that include electron microscopy, hydrodynamic diameter, and optical data for each batch to guarantee products meet specifications. Contract manufacturing is performed on scales that range from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials are produced in our ISO13485 and cGMP compliant cleanroom facility. By leveraging our unique library of nanomaterials, we aim to help our customers rapidly bring nano-enabled products from concept to commercialization.
Stratech Scientific Ltd. provides over 1.8 million innovative and specialist life science research tools to life science researchers who need consistent, reproducible results. Stratech has built an excellent reputation over 34 years for supplying high quality, competitively priced, reliable products to their end users. The company supplies one of the largest ranges of primary and secondary antibodies and they offer specialist reagents within the fields of immunology, neurology, cell invasion, thrombolysis, apoptosis and molecular biology. Stratech is also ISO9001:2008 accredited ensuring superior quality and service for our customers.
The nanoComposix products fit well with Stratech product lines which are used for diverse techniques such as immunochemistry, fluorescent labelling, protein purification and expression, tissue culture, ion channel indication, microarrays and clinical testing. Both companies look forward to working together to provide excellent customer service to customers in the UK in the coming years.
The press release can be found on the nanocomposix website link here: nanocomposix.com/blogs/news/nanocomposix-signs-agreement-with-stratech-ltd-for-distribution-of-its-products-in-the-united-kingdom
The nanoComposix website is: nanocomposix.com
The Stratech Scientific website is: stratech.co.uk
We are a San Diego, California company that fabricates nanomaterials with an unprecedented level of quality and control. Our multi-disciplinary technical teams utilize a proprietary nanoscale tool-kit to develop custom nanomaterials for commercial, academic and government clients for biotechnology, electronics, material science, defense and aerospace applications. Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. nanoComposix markets their products directly and through distributors and licensing partners worldwide.
Contact:
Elizabeth Ward
nanoComposix, Inc.
4878 Ronson Court, Suite K
San Diego, CA 92111
Tel: +1 (858) 565-4227
Fax: +1 (619) 330-2556
Email: elizabeth.ward@nanocomposix.com
Website: nanocomposix.com
Contact:
Sian Bolitho
Stratech Scientific, Ltd
Unit 7, Oaks Drive
Newmarket, Suffolk
United Kingdom CB8 7SY
Tel: +44 (0) 1638 782600
Email: sian@stratech.co.uk
Website: stratech.co.uk